Skip to main content

Table 2 Difference in clinicopathological features due to TILs in younger and elderly patients

From: Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age

Parameters Tumor-infiltrating lymphocytes (n = 191)
Low (n = 96) High (n = 95) p value
Age (years)
 ≤ 45 31 (32.3%) 44 (46.3%) 0.047
 > 60 65 (67.7%) 51 (53.7%)
Tumor size (mm)
 ≤ 20.0 20 (20.8%) 14 (14.7%) 0.271
 > 20.0 76 (79.2%) 81 (85.3%)
Skin infiltration
 Negative 71 (74.0%) 87 (91.6%) 0.001
 Positive 25 (26.0%) 8 (8.4%)
Lymph node status
 Negative 33 (34.4%) 39 (41.1%) 0.341
 Positive 63 (65.6%) 56 (58.9%)
Estrogen receptor
 Negative 37 (38.5%) 67 (70.5%) < 0.001
 Positive 59 (61.5%) 28 (29.5%)
Progesterone receptor
 Negative 55 (57.3%) 76 (80.0%) 0.001
 Positive 41 (42.7%) 19 (20.0%)
Hormone receptor
 Negative 35 (36.5%) 66 (69.5%) < 0.001
 Positive 61 (63.5%) 29 (30.5%)
HER2
 Negative 69 (71.9%) 47 (49.5%) 0.002
 Positive 27 (28.1%) 48 (50.5%)
Ki67
 ≤ 14% 37 (38.5%) 25 (26.3%) 0.071
 > 14% 59 (61.5%) 70 (73.7%)
ORR
 Non-responders 18 (18.8%) 4 (4.2%) 0.002
 Responders 78 (81.2%) 91 (95.8%)
Pathological response
 Non-pCR 79 (82.3%) 45 (47.4%) < 0.001
 pCR 17 (17.7%) 50 (52.6%)
  1. TILs tumor-infiltrating lymphocytes HER, human epidermal growth factor receptor, ORR objective response rate, CR complete response